• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Reed-Lane

    PCI Pharma Services

    Baxter BioPharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    PCI Pharma Services

    Adare Pharma Solutions

    Alcami

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Seasonal Vaccine Manufacturing

    Experience can increase speed and assurance of delivery.

    Seasonal Vaccine Manufacturing
    Seasonal Vaccine Manufacturing
    Table 1. Influenza Vaccine Doses Distributed in the United States, By Season
    Seasonal Vaccine Manufacturing
    Figure 1. Culture of Execution and Continuous Improvement
    Related CONTENT
    • Asymchem
    • Mogene
    • MIDI Labs
    • Reed-Lane
    • Vetio Animal Health
    Wendy Saffell-Clemmer, Lead Scientist, R&D, Senior Director Baxter Pharmaceuticals & Baxter Biopharma Solutions05.07.19
    The number of seasonal influenza vaccine doses in the U.S. has increased 10-fold since 1980 (Table 1) with 169.1 million doses distributed in the U.S. during the 2018-2019 season.1 The development of seasonal influenza vaccines is a carefully choreographed effort beginning with a meeting by an FDA advisory committee in March2 to decide which strains to include in the next season’s vaccine, followed by production of potency standards—in parallel with manufacturers’ preparations—for the new campaign. Seasonal influenza vaccines are unique as their limited time span from strain selection to distribution requires most vaccine producers to rely on outsourcing partners to mitigate risk and ensure timely production. Demand for contract manufacturing organizations (CMOs) support for seasonal influenza vaccines is expected to increase as the seasonal influenza vaccine market is projected to reach more than $4 billion by the end of 2022.3 

    While many CMOs claim vaccine fill-finish experience,4 seasonal campaigns present logistical challenges that few outsourcing partners are prepared to accommodate. Successful contract manufacturing of seasonal vaccine products requires the right facility, culture, and expectations to help ensure quality and on-time delivery. What should sponsors look for when evaluating contract manufacturing services for a new seasonal vaccine program? 


    Table 1. Influenza Vaccine Doses Distributed in the United States, By Season

    Facility and technical capabilities
    Sponsors of seasonal vaccines should seek a partner with extensive experience in the production of pre-filled syringe (PFS) products as well as experience with vaccines and suspensions. An experienced partner can work with the product owner to understand their vaccine’s critical quality attributes (CQAs) and, by leveraging their experience with other suspension products, will be able to readily identify the critical process parameters (CPPs) within their control that may impact the CQAs. Examples of potential CPPs include recirculation, pumping mechanism, and temperature control. Suspension products may require intermittent or constant recirculation to ensure homogeneity of product potency throughout the filling process and the manufacturer should have the experience to make a recommendation of recirculation parameters and mixing speed of the tank to ensure adequate dispersion of suspended solids. In addition, studies are needed to understand the impact of solution level in the tank and mixing speed on the acceptability of the suspension remaining in the tank near the end of the process. To ensure optimization of mixing and recirculation processes, manufacturers must be experienced and proficient at monitoring in-process homogeneity of filled units within the production process using turbidimetric and spectroscopic techniques. 

    The fill mechanism itself may impact product quality. PFS filling lines were historically equipped with rotary piston pumps, but concern over protein aggregation has resulted in an increase in utilization of peristaltic pumps for biologic products. Generally, piston pumps offer greater accuracy and speed, but advances in peristaltic pump head design, drive motors, and calibration algorithms have narrowed differences in performance for all but the most viscous formulations.5 As high throughput is critical for seasonal vaccine manufacturing, lines equipped with modern rotary piston pumps capable of filling 500 units/minute are preferred, but the availability of alternative fill mechanisms may be beneficial if development studies indicate that shear impacts product quality. 

    Ideally, flexibility should extend beyond filling mechanism. Vaccine producers may wish to ship formulated vaccine as a sterile bulk suspension, with no sterile filtration intended prior to filling. In this scenario, the CMO’s experience performing aseptic connections should be scrutinized. Alternatively, sterile filtration of formulated vaccine may be required.  While disposable product contact equipment may be an option, durable equipment is more commonly used in seasonal vaccine production to reduce cost. The proposed new USP chapter <665> Plastic Materials, Components, and Systems Used in the Manufacturing of Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products6 will increase the testing required to demonstrate compatibility with disposable bags and may create additional barriers to the use of plastic single use materials for vaccine production. The CMO should have a robust cleaning validation program to support the use of durable equipment and have the scientific knowledge to be able to apply a risk-based approach to cleaning validation. Additionally, the CMO should be able to develop a residue detection method, and the method validation should include recovery from surfaces using sample coupons of surface materials using the sampling methods utilized in manufacturing. For example, once a residue detection method and cleaning validation process are developed and validated, they may not require revalidation for subsequent campaigns. An evaluation of strain and formulation changes, in collaboration with the sponsor, should be performed to determine change management for validated processes.

    While the formulation and filling process tends to receive the greatest scrutiny in the evaluation of potential manufacturing partners, sponsors should evaluate the technical capabilities in the inspection, labeling, and packaging process as well. The high-throughput and speed required for production of a seasonal vaccine will require the use of automated inspection systems. Automated inspection processes must be validated specifically for each product, though revalidation would not be required for subsequent campaigns if the product change is limited to strain substitution. Vaccine developers should seek a service provider with strong experience in automated inspection of PFS and experience validating automated inspection of semi-transparent fluids. Parameters to be evaluated during development of the inspection process should include temperature of the product as this can have a significant effect on the rejection of syringes during automated inspection of some products. Inspection soon after removal of the filled units from 2-8°C storage can result in precipitation of formulation components which can lead to rejects. The precipitated particles would dissolve as the product temperature approached RT resulting in acceptable units.

    The Drug Supply Chain Security Act7 (passed as part of the Drug Quality and Security Act) requires serialization of product units. While serialization is straightforward when only one product manufacturing site is utilized, the volume of units required by major seasonal vaccine manufacturers will require that vaccine sponsors utilize any internal capacity as well as one or more CMOs. While all CMOs should now be prepared to meet serialization requirements, it is critical that the information technology systems supporting serialization can communicate with the sponsor’s system to ensure that the serial numbers applied are unique and traceable across the network of product manufacturing sites utilized.

    Lastly, because of the time-critical nature of seasonal vaccine production, sponsors should evaluate redundancy at their potential CMO. Redundant filling lines, supplied with separate water and HVAC systems, can provide the ultimate assurance of delivery, though sponsors should balance their desire for risk reduction with the cost of performing process validation on a second line. Implementation of a second redundant packaging line has less of a validation barrier, and can provide risk mitigation as well as increased capacity, particularly in cases when an inventory of filled units has been built and stored.

    Culture of speed and execution
    Strong experience and technical capabilities are critical to success of any project, but the unique time constraints associated with seasonal products require a culture of speed and focus on execution. One area where planning and execution are critical is in supply chain logistics. The potential CMO should be able to articulate and have demonstrated best practices in supplier planning. These include having redundant suppliers for PFS components qualified in their supplier quality system with these redundant components qualified to run on automated filling and inspection lines. The CMO should build strong communication channels with vendors, and these suppliers should be queued and prepared to react and deliver quickly. For example, packaging artwork requires FDA approval, creating a stage gate for the start of automated inspection and packaging campaigns. Strong vendor relationships and preparation can shrink the time required for delivery of printed labels and packaging material after artwork approval from weeks to several days. Ample cold storage capacity can provide logistical advantages as well. Sufficient cold storage can allow for pre-shipment of bulk vaccine by the sponsor and staging of initial supplies at the fill facility. Additionally, capacity for cold storage of work-in-progress (WIP) materials can allow for inventory build-up of filled units while awaiting artwork approval.  Upon approval, the pre-produced inventory of filled units can be inspected, labeled, and packaged using redundant automated lines to expedite delivery.

    The quality team must also demonstrate the culture of execution while maintaining focus on compliance and product quality. Having individuals from the incoming Quality Control team present at the fill facility can result in expedited active pharmaceutical ingredient (API) and material release for supplies received just in time. Other best practices include having a dedicated team of consistent reviewers who can expedite review and release of documentation. This dedicated team should develop a collaborative relationship with the sponsor to ensure rapid closures of any investigations and non-conformance reviews (NCR) which would otherwise delay batch release. 

    Having on-site technical experts from R&D can also expedite investigation closures. One example of a competency that sponsors should evaluate at potential partners is the ability to rapidly identify particles using technologies such as digital microscopy, FTIR microscopy, Scanning-Electron Microscopy (SEM) and Elemental Dispersive Spectroscopy (EDS). Immediate on-site particle identification can determine if they are intrinsic or foreign and speed closure of investigations to meet batch release targets.

    Lastly, the facility should have a plan to staff seasonal campaigns quickly and shift resources as project demand moves from filling to packaging. Ideally, this is accomplished through cross-training so that experienced personnel familiar with the product can move seamlessly between manufacturing tasks to best meet product resource demands. A facility accustomed to year-around 24/7 operations can maximize equipment utilization to offer efficient production. 

    Expectations and continuous improvement
    A successful long-term collaboration with a CMO requires clear, mutually agreed upon expectations as well as a shared culture of continuous improvement. Clear expectations start in the contracting process, and an experienced service provider will have a contract team and a project management team experienced with seasonal products and their unique requirements. One example of a contractual term that is unique to seasonal products is the inclusion of provisions for a flexible start window for filling and packaging operations. Proactive facility capacity management within the flexible start window can allow for dynamic scheduling by the project management team, resulting in manufacturing start within 48 hours of notice by the vaccine sponsor.

    An experienced CMO understands that seasonal vaccine manufacturing is a full-year process. While it may be possible to muscle through a campaign, consistent success and on time delivery requires year-round planning. For example, the facility change control management process must be monitored, and changes to the lines or facility during the seasonal campaign season that could result in a CBE-30 must be avoided. The project management team should work closely with the facility maintenance and regulatory affairs teams to ensure that upgrades and changes be planned proactively to avoid any delays in approval of the annual vaccine product. Maintenance of filling and packaging lines used for a seasonal campaign product should be proactively performed during the season prior to the campaign to avoid any preventable service interruptions. Additionally, during the annual planning period the CMO can prepare for the next campaign by assessing any changes to the vaccine and the impact this may have on any validated processes such as product contact equipment cleaning, communicating with vendors to ensure supply of components, updating and validating any API release testing procedures, and conducting product specific training for manufacturing operators and laboratory analysts.

    Each campaign should end with a collaborative review by the sponsor and the CMO of what went well, what didn’t go well and areas for improvement. Any lessons learned can be incorporated by the CMO during the planning process for the following campaign. 


    Figure 1. Culture of Execution and Continuous Improvement

    Conclusion
    Seasonal vaccine products place unique demands on CMOs. When seeking an external manufacturing partner, vaccine developers should look beyond the manufacturing capabilities visible on a tour and probe specific knowledge about risk analysis and redundancy of equipment as well as ability to comply with serialization requirements for a product manufactured at multiple facilities. Even more important and difficult to assess is the service provider’s culture. Does the CMO have strong component and vendor supplier relationships and do they have a culture of planning that allows for rapid execution on short notice? Does the CMO offer the flexibility of start time and resource staffing to meet changing demands? Lastly, does the CMO work collaboratively with the customer, embracing lessons learned sessions and constructive feedback that can be incorporated into future campaigns? A culture of execution and continuous improvement is a critical factor in meeting the requirements for speed and reliability required by modern high-volume seasonal vaccine campaigns.

    References
    1. https://www.cdc.gov/flu/about/qa/index.htm, accessed March 29, 2019.
    2. FDA’s Critical Role in Ensuring Supply of Influenza Vaccine https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm336267.htm,  accessed March 29, 2019
    3. https://www.medgadget.com/2018/07/seasonal-influenza-vaccine-market-to-reach-more-than-us-4-billion-in-7mm-country-outlook-vaccination-analysis-pipeline-insights-to-2022.html, accessed March 29, 2019.
    4. https://www.contractpharma.com/csd/contract-services-directory/manufacturing-vaccines/, accessed March 29, 2019. 
    5. Lambert P, “Dispensing Biopharmaceuticals with Piston and Peristaltic Pumps”.  Pharmaceutical Technology, http://www.pharmtech.com/dispensing-biopharmaceuticals-piston-and-peristaltic-pumps, September 2008, accessed March 29, 2019.
    6. USP Proposed Chapter (665) Plastic Materials, Components, and Systems Used in the Manufacturing of Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products, PF 43(3) [May–June 2017].
    7. https://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm, accessed April 1, 2019.
    Related Searches
    • facility
    • pipeline
    • filtration
    • Aseptic
    Suggested For You
    Asymchem Asymchem
    Mogene Mogene
    MIDI Labs MIDI Labs
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    The Biopharma Frontier The Biopharma Frontier
    Process Validation in Biologics Development Process Validation in Biologics Development
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Data Management in the Face of Growing Trial Complexity Data Management in the Face of Growing Trial Complexity
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    Clinical Manufacturing on Time and within Budget Clinical Manufacturing on Time and within Budget
    Lonza Establishes Custom Cell Biology Services Lonza Establishes Custom Cell Biology Services
    Flamma Opens New cGMP Kilo Lab in Italy Flamma Opens New cGMP Kilo Lab in Italy
    Full Service Contract Manufacturing Full Service Contract Manufacturing

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20


    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20


    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20


    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login